S3 Med Pharma India Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 10.00 K
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
About S3 Med Pharma India
S3 Med Pharma India Private Limited (SMPIPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 06 July 2021 (Three years and six months 24 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Ethirajulu Suresh, Venkat Babu, and Venkat Indumathi serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24239KA2021PTC149148
- Company No.
149148
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jul 2021
- Date of AGM
29 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at S3 Med Pharma India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ethirajulu Suresh  | Director | 06-Jul-2021 | Current |
| Venkat Babu | Director | 06-Jul-2021 | Current |
| Venkat Indumathi | Director | 06-Jul-2021 | Current |
Financial Performance of S3 Med Pharma India.
S3 Med Pharma India Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of S3 Med Pharma India?
Unlock access to S3 Med Pharma India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
3S Labs Innovations India Private LimitedEthirajulu Suresh, Venkat Babu and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at S3 Med Pharma India?
S3 Med Pharma India has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S3 Med Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S3 Med Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.